Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories anticipates its organic sales growth to remain robust, with projections for 2025 set between 6.0-7.0%, while achieving a 6.4% year-over-year increase with consensus sales of approximately $44.69 billion. Significant growth across its Electrophysiology, Structural Heart, and Diabetes segments, with organic increases of 13.7%, 11.3%, and 16.2% respectively, underlines the company’s expanding market presence and product adoption, particularly noted in emerging markets. Abbott's steadfast commitment to increasing dividends for over 50 consecutive years, coupled with a strong balance sheet, positions the company favorably for future growth and potential mergers and acquisitions.

Bears say

Abbott Laboratories is facing significant challenges due to ongoing Covid-19 testing revenue declines, with Q3'25 sales dropping to $69 million from $265 million in Q3'24, prompting a reevaluation of its sales outlook. Additionally, macroeconomic pressures such as inflation and foreign exchange fluctuations are contributing to lower-than-expected revenues and complicating the company's performance. Finally, the company has expressed concerns over specific product demand sensitivity, particularly with Cologuard, as well as the negative impact of funding cuts for HIV testing on its Rapid Diagnostics segment.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.